Format

Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2013 Feb 1;207(3):493-6. doi: 10.1093/infdis/jis710. Epub 2012 Nov 29.

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

Author information

  • 1Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. graczniak@cdc.gov

Abstract

The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.

PMID:
23204169
PMCID:
PMC3611760
DOI:
10.1093/infdis/jis710
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center